Business Context and Reporting Period
This Form 8-K Current Report was filed by Silo Pharma, Inc. on July 6, 2021. The filing discloses the entry into a material definitive agreement and an amendment to a prior agreement with the University of Maryland, Baltimore (UMB).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed is a research fee payable to UMB described as being in the "low six digits."
Material Changes and Agreements
- Sponsored Research Agreement: On July 6, 2021, the Company entered into an agreement with UMB to evaluate the pharmacokinetics of dexamethasone delivered via liposome to arthritic rats.
- Cost: Fee in the low six digits.
- Timeline: Commences September 1, 2021, continuing until substantial completion.
- Termination: Either party may terminate with 30 days' notice. Early termination by the Company (for non-breach reasons) requires relinquishing rights to results and paying all incurred costs.
- Intellectual Property Option: UMB granted the Company an option to negotiate an exclusive license to any UMB Arising IP or Joint Arising IP. The Company must exercise this option within 60 days of receiving notice of such IP.
- Amendment to Prior Agreement: The Company amended its Commercial Evaluation and License Agreement (CELA) dated February 26, 2021, extending the term by 6 months to February 25, 2022. If the IP Option is exercised, the CELA will expire upon execution of a master license agreement or at the end of the negotiation period.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on financial outlook, or a discussion of general risks beyond the contractual terms of the new agreement. The primary contingency noted is the potential loss of research results and obligation to pay accrued costs if the Company terminates the research agreement early without cause.
Key Facts for Investor Verification
- Verify the exact dollar amount of the "low six digits" research fee in the full text of Exhibit 10.1.
- Confirm the status of the Company's cash reserves to ensure it can fund the research fee and potential termination costs.
- Monitor the 60-day window for exercising the IP option once UMB notifies the Company of Arising IP.
- Review the definition of "Results" and "Joint Arising IP" in the exhibits to understand the scope of potential asset acquisition.